Cardiff Oncology (CRDF) Reports Q2 Loss, Lags Revenue Estimates
This quarterly report represents an earnings surprise of -10.53%. A quarter ago, it was expected that this molecular diagnostic company would post a loss of $0.19 per share when it actually produced a loss of $0.2, delivering a surprise of -5.26%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Cardiff Oncology, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.12 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 19.33%. This compares to year-ago revenues of $0.16 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Cardiff Oncology shares have lost about 14.1% since the beginning of the year versus the S&P 500's gain of 8.6%.
What's Next for Cardiff Oncology?
While Cardiff Oncology has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Cardiff Oncology was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.21 on $0.15 million in revenues for the coming quarter and -$0.77 on $0.57 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 38% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Regeneron (REGN), has yet to report results for the quarter ended June 2025. The results are expected to be released on August 1.
This biopharmaceutical company is expected to post quarterly earnings of $8.03 per share in its upcoming report, which represents a year-over-year change of -30.5%. The consensus EPS estimate for the quarter has been revised 6.5% lower over the last 30 days to the current level.
Regeneron's revenues are expected to be $3.34 billion, down 5.7% from the year-ago quarter.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Cardiff Oncology, Inc. (CRDF) : Free Stock Analysis Report
Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Trump, Carney to speak soon, Canadian official says
WASHINGTON (Reuters) -President Donald Trump and Canadian Prime Minister Mark Carney will likely talk "over the next number of days" after the U.S. imposed a 35% tariff on goods not covered by the U.S.-Mexico-Canada trade agreement, a Canadian official said on Sunday. Dominic LeBlanc, the federal cabinet minister in charge of U.S.-Canada trade, told CBS News' "Face the Nation" that he believes there is an option of striking a deal that will bring down tariffs. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 minutes ago
- Yahoo
Women call the shots across the supply chain at tequila brand 1953
Listen and subscribe to The Big Idea on Apple Podcasts, Spotify, or wherever you find your favorite podcasts. When Shivam Mallick Shah and Lindsey Davis Stover founded the tequila brand 1953, they wanted to make moves in an industry that was becoming increasingly popular among their own demographic while also opening doors for other women. As the brand proudly states on its website, 1953 is "Founded, Farmed, Distilled, and Led by Women." On Yahoo Finance's The Big Idea podcast, the two entrepreneurs shared how they managed to pull off such a feat in a historically male-dominated industry. (Watch the full episode above; listen-only below.) "I just kind of got down this rabbit hole of where the women in tequila are, unfortunately, really hard to find. So that kind of led us to this idea," Davis Stover, a Texas native, said on the podcast. "We were drinking tequila. Every woman we knew is drinking tequila," she continued. "So we wanted to create a company that was founded, farmed, distilled, and led by women at every single level. Even our name, 1953, is the year women earned the right to vote in Mexico. I think that is just the essence of our company and providing opportunities for women." This embedded content is not available in your region. "People didn't think it was necessary to have a female-led supply chain," Shah said. "They didn't think that it would make a difference in the quality of the product, and they didn't think that, frankly, we could do it. They had a lot of strong opinions on what we could do, and it was different than what we wanted to do." Shah and Davis Stover tackled their mission by completing their search in an "organic way," talking with people who worked at distilleries and farms in Mexico. Eventually, they found Carmen and Adriana, who ran the family-owned distillery that 1953 would eventually use. "Their family has owned this distillery for over a hundred years, and they have trained a female master distiller, Rocio Rodriguez, who signs every bottle," Shah explained. "She had this incredible story of having come to this distillery when she was pregnant. She was trained as a chemical engineer, but she was worried about losing her job. Carmen and Adriana's families decided to build a nursery so she could come to work and bring her whole self, which has, of course, changed her life, but it changed so many people's lives." Though their journey to creating a brand with a strong female focus had its roadblocks, the biggest hurdle was finding a woman-owned agave farm. Traditionally, agave farms in Mexico are passed down from father to son, but Carmen and Adriana helped the entrepreneurs find the farm they partner with today. "We could not find an agave farm owned by women," Shah said. "Carmen and Adriana helped us find a gentleman who only had four daughters. We met with them, and we talked about what we were trying to build. We asked him if he would consider passing his farm down to his daughters if we guaranteed purchase of agave from their farms for 1953." After a family meeting in which the four women discussed the proposition with their husbands and father, they ultimately agreed, deciding to take on the responsibility and risk to help complete 1953's women-led supply chain. "They had grown up on this farm, and they knew it like the back of their hand, but they never saw themselves as CEOs. They never saw themselves as the people in charge of running the farm," Shah explained. "What made them think differently was the high school down the street and all the girls who were in that high school, just like they used to be, and wanting to let those girls know that there was nothing they couldn't do. ... It was a motivation we all shared, and we knew we had an alignment of our values, which told us we were in the right place. And that really completed our supply chain." Every Thursday, Elizabeth Gore discusses real-life stories and smart strategies for launching a small business on The Big Idea podcast. You can find more episodes on our video hub or watch on your preferred streaming service. Sign up for the Mind Your Money newsletter Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 minutes ago
- Yahoo
Rail customers urge regulators to block Union Pacific-Norfolk Southern deal, FT reports
(Reuters) -U.S. railroad customer groups have demanded regulators block or put onerous conditions on the proposed merger of Union Pacific and Norfolk Southern, the Financial Times reported on Sunday. Seven associations of shippers have expressed concern the planned deal would significantly increase the power of the merged railroad to raise prices or reduce service standards, the report said. Last month, Union Pacific said it would buy smaller rival Norfolk Southern in an $85 billion deal to create the first U.S. coast-to-coast freight rail operator and reshape the movement of goods from grains to autos across the country. The two railroads are expected to have a combined enterprise value of $250 billion and would unlock about $2.75 billion in annualized synergies, the companies said. Reuters could not immediately verify the FT report. Norfolk Southern and Union Pacific did not immediately respond to Reuters' requests for comment. Previously, the transportation division of SMART, the International Association of Sheet Metal, Air, Rail and Transportation Workers, said it plans to oppose the merger when it comes before the Surface Transportation Board for review. Major railroad unions have long opposed consolidation, arguing such mergers threaten jobs and risk disrupting rail service. Senate Democratic leader Chuck Schumer also criticized the merger saying the deal would push "us even further down the road of dangerous consolidation and monopoly power ... This is a hostile takeover of America's infrastructure."
